Tag: AI Drug Discovery
-
AI and Biology: Transforming Drug Discovery to Precision Engineering
Vijay Pande’s VZVC is pioneering a shift in biology from discovery to engineering, driven by AI’s ability to design drugs with precision. This transformation promises to revolutionize drug discovery, though clinical trials remain a bottleneck. Read more
-
AI-Driven Co-Scientist Revolutionizes Experimental Design
Co-Scientist, an AI platform, is transforming experimental design by analyzing complex data to suggest novel scientific hypotheses. This advancement could accelerate drug discovery and other research fields, leading to faster scientific breakthroughs. Read more
-
AlphaFold’s Homodimer Predictions: A Leap in Drug Discovery
The expansion of AlphaFold to include homodimer predictions significantly enhances drug discovery processes. By providing precise models of protein interactions, it opens new avenues for targeted therapies. Read more
-
Agentic AI Enters the Drug Discovery Lab Bench
Ono Pharmaceutical is embedding Phylo’s Biomni Lab agentic AI platform across its discovery science teams, tasking AI agents with synthesizing internal experimental history, framing hypotheses, and designing experiments in real time alongside scientists. The move reflects a specific theory about where drug discovery loses time — not in individual experiments, but in the cognitive overhead… Read more
-
AI-Directed Robotic Labs Are Rewriting Antibody Development Timelines
MegaRobo’s Megalaxy Laboratory in Suzhou completed 56 rounds of antibody optimization experiments in four months using eight researchers, reporting prediction accuracy gains from 70 to 90 percent across stability, expression, toxicity, and binding affinity. The system’s closed-loop architecture — AI agents directing robotic hardware and updating experimental choices from real wet-lab results — represents a… Read more
-
Cytosurge’s FluidFM®: Pioneering Causal Data in AI Drug Discovery
Cytosurge’s FluidFM® technology is pioneering causal data collection in AI drug discovery, enabling precise analysis of living cells. This advancement could significantly improve drug target identification and reduce failure rates in clinical trials. Read more
-
AI Models Enable Breakthroughs in Drug Repurposing Strategies
Miles Wang, an OpenAI researcher, is launching a startup focused on leveraging AI to repurpose existing drugs, potentially accelerating drug discovery and reducing costs. This approach utilizes AI models to analyze complex datasets for novel therapeutic applications, paving the way for faster, more efficient drug development. Read more
-
AI-Powered Drug Discovery: Transforming Cancer Therapy Selection
Ardigen and VERAXA Biotech are collaborating to enhance cancer therapy development through AI-driven target pair selection, aiming to optimize T cell engagers and antibody-drug conjugates. This approach could significantly improve patient outcomes by minimizing side effects and improving therapeutic efficacy. Read more
-
AI-Driven Innovations Accelerate India’s Novel Drug Discovery Landscape
India’s life sciences sector is rapidly transforming through AI-driven innovations in drug discovery, highlighted in a recent report by BCG and HealthKois. The integration of AI technologies is accelerating the development of novel therapeutics and positioning India as a potential leader in global pharmaceutical innovation. Read more
-
AI Collaboration Advances Precision Cancer Therapy Development
A new collaboration between Ardigen and VERAXA Biotech aims to enhance cancer therapies by optimizing target selection using advanced AI techniques. This partnership could significantly improve treatment efficacy while minimizing toxicity, marking a pivotal moment in the application of AI in cancer drug development. Read more
